Multivariate analysis on transplant outcomes stratified by the RICE score
| . | Low RICE score (0-1) . | High RICE score (2-3) . | ||
|---|---|---|---|---|
| HR (95% CI) . | P values . | HR (95% CI) . | P values . | |
| Training cohort | ||||
| NRM | ||||
| Myeloablative | 1 | Ref | 1 | Ref |
| Reduced intensity | 0.99 (0.85-1.15) | .860 | 0.73 (0.60-0.90) | .003 |
| Relapse | ||||
| Myeloablative | 1 | Ref | 1 | Ref |
| Reduced intensity | 1.05 (0.88-1.25) | .570 | 1.04 (0.82-1.33) | .740 |
| OS | ||||
| Myeloablative | 1 | Ref | 1 | Ref |
| Reduced intensity | 0.96 (0.85-1.08) | .457 | 0.76 (0.65-0.90) | .001 |
| Validation cohort | ||||
| NRM | ||||
| Myeloablative | 1 | Ref | 1 | Ref |
| Reduced intensity | 0.81 (0.66-1.01) | .061 | 0.57 (0.43-0.77) | <.001 |
| Relapse | ||||
| Myeloablative | 1 | Ref | 1 | Ref |
| Reduced intensity | 1.24 (0.97-1.58) | .088 | 1.47 (1.02-2.12) | .037 |
| OS | ||||
| Myeloablative | 1 | Ref | 1 | Ref |
| Reduced intensity | 0.93 (0.79-1.11) | .422 | 0.79 (0.63-0.99) | .048 |
| . | Low RICE score (0-1) . | High RICE score (2-3) . | ||
|---|---|---|---|---|
| HR (95% CI) . | P values . | HR (95% CI) . | P values . | |
| Training cohort | ||||
| NRM | ||||
| Myeloablative | 1 | Ref | 1 | Ref |
| Reduced intensity | 0.99 (0.85-1.15) | .860 | 0.73 (0.60-0.90) | .003 |
| Relapse | ||||
| Myeloablative | 1 | Ref | 1 | Ref |
| Reduced intensity | 1.05 (0.88-1.25) | .570 | 1.04 (0.82-1.33) | .740 |
| OS | ||||
| Myeloablative | 1 | Ref | 1 | Ref |
| Reduced intensity | 0.96 (0.85-1.08) | .457 | 0.76 (0.65-0.90) | .001 |
| Validation cohort | ||||
| NRM | ||||
| Myeloablative | 1 | Ref | 1 | Ref |
| Reduced intensity | 0.81 (0.66-1.01) | .061 | 0.57 (0.43-0.77) | <.001 |
| Relapse | ||||
| Myeloablative | 1 | Ref | 1 | Ref |
| Reduced intensity | 1.24 (0.97-1.58) | .088 | 1.47 (1.02-2.12) | .037 |
| OS | ||||
| Myeloablative | 1 | Ref | 1 | Ref |
| Reduced intensity | 0.93 (0.79-1.11) | .422 | 0.79 (0.63-0.99) | .048 |
All models were adjusted for recipient’s age, sex mismatch disease, DRI, KPS, HCT-CI, donor source, GVHD prophylaxis, in vivo T-cell depletion, and the year of receiving HCT.